Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH Cash-to-Debt is 0.00 as of Jun. 2026. The stock has 6 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 483091.3% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ProPhase Labs's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.00.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, ProPhase Labscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for ProPhase Labs's Cash-to-Debt or its related term are showing as below:
During the past 13 years, ProPhase Labs's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 1.81.
PRPH's Cash-to-Debt is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.98 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
ProPhase Labs Cash-to-Debt Related Terms
ProPhase Labs Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
PRPH vs NOTVQ, NSTM, FUNI: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a Cash-to-Debt of 0.00 as of Jun. 2026. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 207 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' Cash-to-Debt too high?
ProPhase Labs' current Cash-to-Debt is 0.00. Based on the distribution chart, ProPhase Labs ranks #999999 out of 207 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Cash-to-Debt compare to NOTVQ and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 207 companies for Cash-to-Debt. This places ProPhase Labs in the lower half of its industry. The industry median Cash-to-Debt is 0.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 0.98, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Cash-to-Debt is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.59, compared to a current price of $0.02 — trading 96.6% below its estimated fair value. The current Cash-to-Debt is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Cash-to-Debt is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
